POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Potassium chloride dissociates to provide potassium ions, which are essential for maintaining intracellular tonicity, nerve impulse transmission, cardiac contractility, and skeletal muscle function. Sodium chloride provides sodium and chloride ions to maintain extracellular fluid osmolarity and volume.
| Metabolism | Potassium is primarily eliminated via renal excretion; no significant hepatic metabolism. |
| Excretion | Renal excretion accounts for approximately 90% of potassium elimination; the remaining 10% is eliminated via the gastrointestinal tract. Minor biliary/fecal loss is negligible in normal physiology. |
| Half-life | The terminal elimination half-life of potassium is approximately 1-1.5 hours in individuals with normal renal function, reflecting rapid renal clearance. In renal impairment, half-life is significantly prolonged, necessitating dose adjustment. |
| Protein binding | Potassium is minimally protein-bound, approximately 5-10%, primarily to albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 0.5-0.7 L/kg, reflecting distribution primarily into extracellular fluid and intracellular uptake via Na+/K+-ATPase. |
| Bioavailability | Bioavailability: Intravenous administration yields 100% bioavailability. Oral bioavailability is approximately 90-100% for soluble potassium salts; not applicable for IV formulation. |
| Onset of Action | Intravenous administration: Clinical effect (e.g., ECG normalization, correction of hypokalemia) occurs within 5-10 minutes following IV infusion. |
| Duration of Action | Intravenous administration: Duration of effect is variable and depends on ongoing potassium losses, renal function, and total body stores; typically maintains serum potassium elevation for 1-2 hours after infusion cessation. |
| Molecular Weight | 74.55 |
20 mEq potassium chloride in 0.9% sodium chloride, intravenous infusion at a rate not exceeding 10-20 mEq/hour; maximum 150 mEq/day.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-50 mL/min: reduce dose by 25-50%; GFR <30 mL/min: avoid or use with extreme caution, consider 50% dose reduction; monitor serum potassium closely. |
| Liver impairment | No specific dose adjustment required for Child-Pugh A or B; Child-Pugh C: cautious use, monitor potassium levels due to risk of hyperkalemia. |
| Pediatric use | Intravenous dose: 0.2-0.5 mEq/kg/hour, maximum 1 mEq/kg/dose or 30 mEq/dose; monitor serum potassium and ECG. |
| Geriatric use | Start with lower end of dosing range (e.g., 10 mEq/hour max) due to age-related decline in renal function; monitor renal function and potassium levels frequently. |
| 1st trimester | Potassium chloride is a normal plasma constituent. No teratogenic effects are expected. Use only if clearly needed and if maternal benefit justifies potential risk. |
| 2nd trimester | No known fetal risk. Monitor maternal potassium levels to avoid hyperkalemia or hypokalemia. |
| 3rd trimester | No known fetal risk. However, hyperkalemia in the mother may cause fetal arrhythmias. Avoid in eclampsia or preeclampsia with renal impairment. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Potassium readily crosses the placenta. Fetal serum potassium levels are similar to maternal levels due to active transport. |
| Breastfeeding | Potassium is a normal component of breast milk. Supplementation with potassium chloride is unlikely to affect the breastfed infant. Monitor maternal electrolytes and avoid excessive doses. |
| Lactation Rating | L1: Safe |
| Teratogenic Risk | Potassium chloride is not teratogenic. No increased risk of fetal malformations has been associated with intravenous potassium administration. However, maternal hypokalemia or hyperkalemia may adversely affect fetal development. In first trimester, maintain normokalemia. Second and third trimesters: risk is from electrolyte imbalance rather than direct teratogenicity. |
| Fetal Monitoring | Monitor serum potassium levels, ECG for hyperkalemia signs (peaked T waves, PR prolongation, QRS widening), and renal function. In pregnancy, monitor for fluid overload and signs of preeclampsia. Fetal heart rate monitoring if maternal electrolyte disturbance or arrhythmias occur. |
| Fertility Effects | No known adverse effects on fertility. Potassium homeostasis is essential for normal reproductive function; severe hypokalemia or hyperkalemia may impair ovulation or spermatogenesis indirectly, but no direct reproductive toxicity. |
■ FDA Black Box Warning
Potassium chloride injection concentrate is for dilution only; must be diluted before use to avoid fatal cardiac arrhythmias or arrest due to rapid administration or high concentration.
| Common Effects | fluid replacement |
| Serious Effects |
HyperkalemiaSevere renal impairment (oliguria, anuria, or during acute renal failure)Addison's diseaseAcute dehydrationHeat crampsConcurrent use of potassium-sparing diuretics or ACE inhibitors with high risk of hyperkalemia
| Precautions | Risk of hyperkalemia, especially in patients with renal impairment, Monitor serum potassium levels and ECG during administration, Use with caution in patients with cardiac disease or receiving digitalis glycosides, Rapid infusion may cause hyperkalemia and cardiac arrest, Solutions containing sodium chloride should be used cautiously in patients with heart failure, hypertension, or fluid retention |
| Food/Dietary | Avoid excessive intake of potassium-rich foods (e.g., bananas, oranges, grapefruit, tomatoes, spinach, potatoes, avocados, dried fruits, nuts, chocolate) and potassium-containing salt substitutes. Concurrent use with ACE inhibitors, ARBs, or potassium-sparing diuretics increases hyperkalemia risk. Alcohol consumption may exacerbate electrolyte imbalances. |
| Clinical Pearls | Potassium chloride 20 mEq in 0.9% sodium chloride is a hypertonic solution (osmolarity ~586 mOsm/L). Administer via central line to avoid peripheral vein phlebitis. Maximum infusion rate: 10 mEq/hour; 20 mEq/hour in monitored ICU setting with cardiac monitoring. Contraindicated in severe renal impairment (GFR < 20 mL/min), hyperkalemia, or Addison's disease. Monitor ECG for peaked T waves, loss of P wave, or widened QRS. Correct hypomagnesemia first to prevent refractory hypokalemia. |
| Patient Advice | This medication is given intravenously to prevent or treat low potassium levels. · You will have frequent blood tests to check your potassium levels. · Report any muscle weakness, tingling, or irregular heartbeats to your nurse immediately. · Do not eat large amounts of high-potassium foods (bananas, oranges, spinach, salt substitutes) unless advised by your doctor. · Tell your healthcare provider if you have kidney problems or take water pills (diuretics). |
Loading safety data…